ArticleDiabetologia2022
Subgroups of patients with young-onset type 2 diabetes in India reveal insulin deficiency as a major driver.
Article in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Clinical and laboratory characteristics of novel diabetes subgroups: A systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Subtypes of pre-diabetes in rural adolescent girls from India (DERVAN-11).BMJ open diabetes research & care · 2026Article
- Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.Diabetologia · 2026Article
- Distinct multi-omics signatures of clinical subgroups of type 2 diabetes define heterogeneous responses to an insulin sensitizer.Nature communications · 2026Article
- Subtypes of Type 2 Diabetes and Prediabetes: Mortality and Excess Life Lost in South Asians.Diabetes care · 2026Article
- Genetic basis of Asian diabetes.Journal of diabetes investigation · 2026Review
- Clinical characteristics, disease course, and clinical subgroups of young adults with type 2 diabetes.Journal of the Endocrine Society · 2026Article
- Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort.Cardiovascular diabetology · 2026Article
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- Type 2 Diabetes in Morocco: Toward a Precision Diabetology, from Pathogenesis to Treatment.Annals of African medicine · 2026Article
- Relationship between Insulin Resistance and Circulating Stem and Progenitor Cells in Newlydiagnosed Youth-onset Type 2 Diabetes.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Phenotypic heterogeneity of type 2 diabetes and risks of all-cause and cause-specific mortality.Cell reports. Medicine · 2025Article
- Non-autoimmune diabetes in young people from Assam, India: the PHENOEINDY-2 study.Diabetologia · 2025Article
- Article
- XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestries.Communications medicine · 2025Article
- Diabetic retinal disease.Nature reviews. Disease primers · 2025Review
- Prediabetes.Nature reviews. Disease primers · 2025Review
- Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities.Diabetologia · 2025Review
- Severe insulin-deficient diabetes is at the opposite end of the neuropathy spectrum to mild aged-related diabetes.Journal of diabetes investigation · 2025Article
- Lessons Learned From Epidemiology of Type 2 Diabetes in South Asians: Kelly West Award Lecture 2024.Diabetes care · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
Abstract
aim/hypothesisFive subgroups were described in European diabetes patients using a data driven machine learning approach on commonly measured variables. We aimed to test the applicability of this phenotyping in Indian individuals with young-onset type 2 diabetes.
methodsWe applied the European-derived centroids to Indian individuals with type 2 diabetes diagnosed before 45 years of age from the WellGen cohort (n = 1612). We also applied de novo k-means clustering to the WellGen cohort to validate the subgroups. We then compared clinical and metabolic-endocrine characteristics and the complication rates between the subgroups. We also compared characteristics of the WellGen subgroups with those of two young European cohorts, ANDIS (n = 962) and DIREVA (n = 420). Subgroups were also assessed in two other Indian cohorts, Ahmedabad (n = 187) and PHENOEINDY-2 (n = 205).
resultsBoth Indian and European young-onset type 2 diabetes patients were predominantly classified into severe insulin-deficient (SIDD) and mild obesity-related (MOD) subgroups, while the severe insulin-resistant (SIRD) and mild age-related (MARD) subgroups were rare. In WellGen, SIDD (53%) was more common than MOD (38%), contrary to findings in Europeans (Swedish 26% vs 68%, Finnish 24% vs 71%, respectively). A higher proportion of SIDD compared with MOD was also seen in Ahmedabad (57% vs 33%) and in PHENOEINDY-2 (67% vs 23%). Both in Indians and Europeans, the SIDD subgroup was characterised by insulin deficiency and hyperglycaemia, MOD by obesity, SIRD by severe insulin resistance and MARD by mild metabolic-endocrine disturbances. In WellGen, nephropathy and retinopathy were more prevalent in SIDD compared with MOD while the latter had higher prevalence of neuropathy. CONCLUSIONS /
interpretationOur data identified insulin deficiency as the major driver of type 2 diabetes in young Indians, unlike in young European individuals in whom obesity and insulin resistance predominate. Our results provide useful clues to pathophysiological mechanisms and susceptibility to complications in type 2 diabetes in the young Indian population and suggest a need to review management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.